A recent study published in Science China Life Sciences demonstrates that disulfiram, a drug used to treat alcoholism, can suppress liver cancer by regulating lipid metabolism and angiogenesis. Researchers found that disulfiram upregulates the gene c-FOS by reducing its RNA methylation, which in turn inhibits key molecules involved in lipid accumulation and blood vessel formation in tumors. This discovery highlights a promising repurposing potential for disulfiram in hepatocellular carcinoma therapy.

A research team led by Prof. Kenward VONG, Assistant Professor from the Department of Chemistry at The Hong Kong University of Science and Technology (HKUST) has recently achieved a significant breakthrough by bioengineering a new type of glycan-targeting system known as “lectin-directed protein aggregation therapy (LPAT)”. Using this technology, they developed a therapy capable of preventing the onset and growth of metastatic breast cancers in mouse models.

Scientists designed vaccines to treat HPV-positive head and neck cancer. All vaccines had the same ingredients but different, strategically designed structures. One vaccine vastly outperformed the others, showing that vaccine design depends on structure as well as medicinal components.

Whole brain radiotherapy (WBRT) saves lives by treating cancer that has spread to the brain, but it also causes long-standing brain damage. Many patients develop memory problems, thinking difficulties, and depression after WBRT. There are currently no medicines that adequately prevent these problems of WBRT. The research team discovered that an experimental neuroprotective drug, P7C3-A20, could protect the brain from these harmful side effects of WBRT in animal models, without impairing the ability of radiation to kill tumor cells. If these findings translate to humans, adding a drug like P7C3-A20 to WBRT could safely and effectively preserve cognition and mood after lifesaving WBRT.

Study to be presented at this year's ESGO 2026 , demonstrates significant overall survival benefit with Elenagen plus Gemcitabine in one of the deadliest gynecologic malignancies